According to Deutsche Bank, United Therapeutics UTHR is downgraded to Hold.
Deutsche Bank said that this morning United Therapeutics announced that the combination trial Freedom - C(2) for Oral Remodulin did not hit primary endpoint. “We expect stock to remain weak due to this news. We calculate fair value of UTHR at $53 in the absence of Oral Remodulin.”
United Therapeutics closed yesterday at $48.76.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in